ESR1 and triple-negative breast carcinoma: Breast cancer subtypes guide the treatment approaches, such as chemotherapy alone for triple-negative breast cancer, endocrine therapy for all HER2-/ER+/PR+ tumor, and immunotherapy (trastuzumab-based HER2-directed antibody) for all HER2+ tumor.